Dr Debra Patt Highlights Payer, Education Considerations in Use of Trastuzumab Deruxtecan for HER2-Low Breast Cancer
DESTINY-Breast04 trial shows strong results for trastuzumab deruxtecan, impacting breast cancer care and highlighting payer, doctor education needs.
According to Debra Patt, MD, PhD, MBA, Executive Vice President, Public Policy, Payer Relations, and Strategic Initiatives at Texas Oncology, results from the DESTINY-Breast04 clinical trial continue to make waves in breast cancer care—while raising considerations for payers and a need for education among doctors. Dr. Patt offered the keynote address at ASCO’s Patient-Centered Oncology Care®, highlighting the dramatic responses seen with trastuzumab deruxtecan in the trial.
Click here to read the full article.
Click here to read the full article.